首页> 外文期刊>Biologicals: Journal of the International Association of Biological Standardization >A time-resolved fluoroimmunoassay for assessing rabies antibody titers in the sera of vaccinated human subjects
【24h】

A time-resolved fluoroimmunoassay for assessing rabies antibody titers in the sera of vaccinated human subjects

机译:用于评估疫苗接种人受试者血清中的狂犬病抗体滴度的时间分辨的氟汞

获取原文
获取原文并翻译 | 示例
           

摘要

Several studies have investigated the use of simple in vitro tests for the assessment of rabies antibody titers in serum samples from vaccinated human subjects, which would allow the effectiveness of rabies vaccination to be conveniently evaluated. To this end, a novel time-resolved fluoroimmunoassay (TRFIA) for the assessment of rabies antibody titers was established in this study for evaluating the effectiveness of protection against rabies. The TRFIA had a satisfactory limit of detection value (0.035 IU/mL) under optimal conditions. Additionally, the application of the TRFIA was demonstrated in 68 serum samples with satisfactory results. The coefficient variations (CVs) were all <10%, and the recoveries were in the range of 90-110%. The correlation coefficient of titer values obtained using the present TRFIA and the rapid fluorescent focus inhibition test (RFFIT) was 0.733, with a coincidence rate regarding the evaluation results (protected or not protected by vaccination) of 100%. The preliminary results confirmed that the TRFIA had a higher performance than an enzyme-linked immunosorbent assay (ELISA), and could potentially replace the ELISA. Based on these results, the novel TRFIA appears to be a convenient tool for the evaluation of rabies vaccination results based on serum samples from vaccinated human subjects.
机译:几项研究调查了使用简单的体外试验来评估接种过狂犬病疫苗的人类受试者血清样本中的狂犬病抗体滴度,这将方便地评估狂犬病疫苗接种的有效性。为此,本研究建立了一种新的时间分辨荧光免疫分析法(TRFIA),用于评估狂犬病抗体滴度,以评估狂犬病防护的有效性。在最佳条件下,TRFIA具有令人满意的检测限(0.035 IU/mL)。此外,在68份血清样本中证明了TRFIA的应用,结果令人满意。变异系数均<10%,回收率在90-110%之间。使用目前的TRFIA和快速荧光焦点抑制试验(RFFIT)获得的滴度值的相关系数为0.733,评估结果(疫苗保护或不保护)的符合率为100%。初步结果证实,TRFIA比酶联免疫吸附试验(ELISA)具有更高的性能,并有可能取代ELISA。基于这些结果,新的TRFIA似乎是一种方便的工具,用于根据接种过疫苗的人类受试者的血清样本评估狂犬病疫苗接种结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号